"The voice for cancer physicians and their patients in Massachusetts."

FDA approval of lymphoma medicine Ukoniq (umbralisib) is withdrawn due to safety concerns

02 Jun 2022 9:01 AM | Katy Monaco (Administrator)

Due to safety concerns, the U.S. Food and Drug Administration (FDA) has withdrawn its approval for the cancer medicine Ukoniq (umbralisib).  Ukoniq was approved to treat two specific types of lymphoma: marginal zone lymphoma (MZL) and follicular lymphoma (FL). More Information

Massachusetts Society of Clinical Oncologists ©2022

860 Winter Street, Waltham, MA, 02451
Tel: 781.434.7329  |  Fax: 781.464.4896  |  email: msco@mms.org

Powered by Wild Apricot Membership Software